Research ExplorerPublicationsSARS-CoV-2 Omicron sublineages exhibit distinct antibody esc...

SARS-CoV-2 Omicron sublineages exhibit distinct antibody escape patterns

Standard

SARS-CoV-2 Omicron sublineages exhibit distinct antibody escape patterns. / Gruell, Henning; Vanshylla, Kanika; Korenkov, Michael; Tober-Lau, Pinkus; Zehner, Matthias; Münn, Friederike; Janicki, Hanna; Augustin, Max; Schommers, Philipp; Sander, Leif Erik; Kurth, Florian; Kreer, Christoph; Klein, Florian.

In: CELL HOST MICROBE, Vol. 30, No. 9, 14.09.2022, p. 1231-1241.e6.

Research output: SCORING: Contribution to journal › SCORING: Journal article › Research › peer-review

Harvard

Gruell, H, Vanshylla, K, Korenkov, M, Tober-Lau, P, Zehner, M, Münn, F, Janicki, H, Augustin, M, Schommers, P, Sander, LE, Kurth, F, Kreer, C & Klein, F 2022, 'SARS-CoV-2 Omicron sublineages exhibit distinct antibody escape patterns', CELL HOST MICROBE, vol. 30, no. 9, pp. 1231-1241.e6. https://doi.org/10.1016/j.chom.2022.07.002

APA

Gruell, H., Vanshylla, K., Korenkov, M., Tober-Lau, P., Zehner, M., Münn, F., Janicki, H., Augustin, M., Schommers, P., Sander, L. E., Kurth, F., Kreer, C., & Klein, F. (2022). SARS-CoV-2 Omicron sublineages exhibit distinct antibody escape patterns. CELL HOST MICROBE, 30(9), 1231-1241.e6. https://doi.org/10.1016/j.chom.2022.07.002

Vancouver

Gruell H, Vanshylla K, Korenkov M, Tober-Lau P, Zehner M, Münn F et al. SARS-CoV-2 Omicron sublineages exhibit distinct antibody escape patterns. CELL HOST MICROBE. 2022 Sep 14;30(9):1231-1241.e6. https://doi.org/10.1016/j.chom.2022.07.002

Bibtex

@article{ac0a878c1e8f4b73a0261d1271795ea2,
title = "SARS-CoV-2 Omicron sublineages exhibit distinct antibody escape patterns",
abstract = "SARS-CoV-2 neutralizing antibodies play a critical role in COVID-19 prevention and treatment but are challenged by viral evolution and the emergence of novel escape variants. Importantly, the recently identified Omicron sublineages BA.2.12.1 and BA.4/5 are rapidly becoming predominant in various countries. By determining polyclonal serum activity of 50 convalescent or vaccinated individuals against BA.1, BA.1.1, BA.2, BA.2.12.1, and BA.4/5, we reveal a further reduction in BA.4/5 susceptibility to vaccinee sera. Most notably, delineation of sensitivity to an extended 163-antibody panel demonstrates pronounced antigenic differences with distinct escape patterns among Omicron sublineages. Antigenic distance and/or higher resistance may therefore favor immune-escape-mediated BA.4/5 expansion after the first Omicron wave. Finally, while most clinical-stage monoclonal antibodies are inactive against Omicron sublineages, we identify promising antibodies with high pan-SARS-CoV-2 neutralizing potency. Our study provides a detailed understanding of Omicron-sublineage antibody escape that can inform on effective strategies against COVID-19.",
keywords = "Antibodies, Monoclonal, Antibodies, Neutralizing, Antibodies, Viral, COVID-19, Humans, Neutralization Tests, SARS-CoV-2, Spike Glycoprotein, Coronavirus/genetics",
author = "Henning Gruell and Kanika Vanshylla and Michael Korenkov and Pinkus Tober-Lau and Matthias Zehner and Friederike M{\"u}nn and Hanna Janicki and Max Augustin and Philipp Schommers and Sander, {Leif Erik} and Florian Kurth and Christoph Kreer and Florian Klein",
note = "Copyright {\textcopyright} 2022 Elsevier Inc. All rights reserved.",
year = "2022",
month = sep,
day = "14",
doi = "10.1016/j.chom.2022.07.002",
language = "English",
volume = "30",
pages = "1231--1241.e6",
journal = "CELL HOST MICROBE",
issn = "1931-3128",
publisher = "Cell Press",
number = "9",

}

RIS

TY - JOUR

T1 - SARS-CoV-2 Omicron sublineages exhibit distinct antibody escape patterns

AU - Gruell, Henning

AU - Vanshylla, Kanika

AU - Korenkov, Michael

AU - Tober-Lau, Pinkus

AU - Zehner, Matthias

AU - Münn, Friederike

AU - Janicki, Hanna

AU - Augustin, Max

AU - Schommers, Philipp

AU - Sander, Leif Erik

AU - Kurth, Florian

AU - Kreer, Christoph

AU - Klein, Florian

N1 - Copyright © 2022 Elsevier Inc. All rights reserved.

PY - 2022/9/14

Y1 - 2022/9/14

N2 - SARS-CoV-2 neutralizing antibodies play a critical role in COVID-19 prevention and treatment but are challenged by viral evolution and the emergence of novel escape variants. Importantly, the recently identified Omicron sublineages BA.2.12.1 and BA.4/5 are rapidly becoming predominant in various countries. By determining polyclonal serum activity of 50 convalescent or vaccinated individuals against BA.1, BA.1.1, BA.2, BA.2.12.1, and BA.4/5, we reveal a further reduction in BA.4/5 susceptibility to vaccinee sera. Most notably, delineation of sensitivity to an extended 163-antibody panel demonstrates pronounced antigenic differences with distinct escape patterns among Omicron sublineages. Antigenic distance and/or higher resistance may therefore favor immune-escape-mediated BA.4/5 expansion after the first Omicron wave. Finally, while most clinical-stage monoclonal antibodies are inactive against Omicron sublineages, we identify promising antibodies with high pan-SARS-CoV-2 neutralizing potency. Our study provides a detailed understanding of Omicron-sublineage antibody escape that can inform on effective strategies against COVID-19.

AB - SARS-CoV-2 neutralizing antibodies play a critical role in COVID-19 prevention and treatment but are challenged by viral evolution and the emergence of novel escape variants. Importantly, the recently identified Omicron sublineages BA.2.12.1 and BA.4/5 are rapidly becoming predominant in various countries. By determining polyclonal serum activity of 50 convalescent or vaccinated individuals against BA.1, BA.1.1, BA.2, BA.2.12.1, and BA.4/5, we reveal a further reduction in BA.4/5 susceptibility to vaccinee sera. Most notably, delineation of sensitivity to an extended 163-antibody panel demonstrates pronounced antigenic differences with distinct escape patterns among Omicron sublineages. Antigenic distance and/or higher resistance may therefore favor immune-escape-mediated BA.4/5 expansion after the first Omicron wave. Finally, while most clinical-stage monoclonal antibodies are inactive against Omicron sublineages, we identify promising antibodies with high pan-SARS-CoV-2 neutralizing potency. Our study provides a detailed understanding of Omicron-sublineage antibody escape that can inform on effective strategies against COVID-19.

KW - Antibodies, Monoclonal

KW - Antibodies, Neutralizing

KW - Antibodies, Viral

KW - COVID-19

KW - Humans

KW - Neutralization Tests

KW - SARS-CoV-2

KW - Spike Glycoprotein, Coronavirus/genetics

U2 - 10.1016/j.chom.2022.07.002

DO - 10.1016/j.chom.2022.07.002

M3 - SCORING: Journal article

C2 - 35921836

VL - 30

SP - 1231-1241.e6

JO - CELL HOST MICROBE

JF - CELL HOST MICROBE

SN - 1931-3128

IS - 9

ER -